An observational study in Pancreatic Cancer, sponsored by Inna Chen, MD. Recruiting at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Inna Chen, MD · Observational
The primary objective of the Copenhagen Pancreatic Cancer (COPAN) study is to describe the real-world population of patients with pancreatic cancer (PC). Larger sample of longitudinal real-world data provides a unique opportunity for comprehensive exploration of the diagnostic and treatment journey for individuals diagnosed with PC and allows to investigate treatment outcomes and associated prognostic factors. Furthermore, the study aims to identify determinants of treatment management and treatment outcomes, including patient-reported outcomes.
The study objective is to describe the real-world population of patients with pancreatic cancer by collecting longitudinal data that facilitates a more rigorous understanding of the PC. This research project will catalog different elements of a patient's diagnostic and treatment journey and identify unmet needs of patients with PC.
The study aims to:
8. To investigate the impact of PC and treatment on patients' quality of life.
4 Study Design This study of patients with PC will employ both a prospective, observational design and retrospective design to capture real-world data relating to health status and/or the delivery of health care routinely collected from a variety of sources. Data will be collected longitudinally, allowing for a dynamic analysis of the disease trajectory.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's planned enrollment of 8,000 is above the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Inna Chen, MD is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with pancreatic cancer referred to Department of Oncology, Herlev Hospital, Denmark within the study period will be invited to participate.
Histologically confirmed pancreatic cancer
Exclusion Criteria:
Overall survival
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inna Chen, MD